BridgeMD
New treatment option for Pancreatic Cancer
Official title Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
ClinicalTrials.gov ID: NCT06435260
What this study is testing
What is Camrelizumab+chemotherapy?
Camrelizumab+chemotherapy is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for pancreatic cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age:18 to 75 years old, male or female;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Tumor was located in the pancreas;
- Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma;
- No distant metastasis;
You likely can't join if
- Patients who did not meet these inclusion criteria;
- Poor cognitive ability, inability to answer questions, inability to fill out questionnaires, or mental disorders;
- The investigators think inappropriate.
See the full eligibility criteria
- Age:18 to 75 years old, male or female;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Tumor was located in the pancreas;
- Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma;
- No distant metastasis;
- The pancreatic tumor is located more than 1cm away from the duodenum；
- Clinical assessment was locally advanced or critical for resectable. Locally advanced pancreatic cancer diagnostic criteria: (1) due to tumor invasion, venous occlusion or involving a wide range of superior mesenteric...
- Patients who did not meet these inclusion criteria;
- Poor cognitive ability, inability to answer questions, inability to fill out questionnaires, or mental disorders;
- The investigators think inappropriate.
The study team makes the final eligibility decision.
Where it's taking place
- Shijiazhuang, Hebei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shijiazhuang, Hebei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.